ErbB2陽性乳がんにおける脳転移に対するラパチニブ

基本情報

NCT ID

NCT00263588

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

242

治験依頼者名

Novartis

概要

Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during the course of the study.

対象疾患

介入

依頼者（Sponsor）